[go: up one dir, main page]

EP0516685A4 - Artificial tears - Google Patents

Artificial tears

Info

Publication number
EP0516685A4
EP0516685A4 EP19910904702 EP91904702A EP0516685A4 EP 0516685 A4 EP0516685 A4 EP 0516685A4 EP 19910904702 EP19910904702 EP 19910904702 EP 91904702 A EP91904702 A EP 91904702A EP 0516685 A4 EP0516685 A4 EP 0516685A4
Authority
EP
European Patent Office
Prior art keywords
carrier
hyaluronic acid
phospholipid
artificial tear
composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP19910904702
Other languages
French (fr)
Other versions
EP0516685A1 (en
Inventor
Brian Andrew Hills
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
MacNaught Pty Ltd
Original Assignee
MacNaught Pty Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by MacNaught Pty Ltd filed Critical MacNaught Pty Ltd
Publication of EP0516685A1 publication Critical patent/EP0516685A1/en
Publication of EP0516685A4 publication Critical patent/EP0516685A4/en
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/683—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
    • A61K31/685—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols one of the hydroxy compounds having nitrogen atoms, e.g. phosphatidylserine, lecithin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents

Definitions

  • the present invention relates to an artificial tear composition and in particular to artificial tear compositions which contain phospholipids, and optionally hyaluronic acid or a salt thereof.
  • an artificial tear composition which ideally would have one or more of the following properties: excellent lubrication to allow effortless sliding of the eyelid over the ocular surface or a contact lens; the capability to provide excellent of lubrication under high load bearing conditions relevant to an ill fitting contact lens and the pressure of high spot as the eye turns; reduction of fluid evaporation to maintain the tear film; reduction of the disjoining pressure tending to rupture the tear films and expose dry spots in the ocular surface; provision of a non-stick surface preventing adhesion of the ocular surface to a contact lens or eyelid; or provision of a biological barrier to invasion of the eye by impinging air-borne pathogens such as bacteria or viruses.
  • a lubricant composition comprising at least one surface active phospholipid, hyaluronic acid or a water soluble salt thereof in saline solution, is effective in the treatment of arthritis, osteoarthritis and rheumatic diseases by improving lubrication of surfaces in particular surfaces in the joints of animals and humans, and acting as a lubricant between tissue surfaces in contact with each other.
  • certain phospholipids especially the disaturated phosphotidylcholines (lecithins) can give coefficients of kinetic friction of less than 0.01 and as low as 0.002. It was also found that these lower coefficients of friction could be
  • Hyaluronic acid is a naturally occurring, high viscosity mucopolysaccharide having alternating ⁇ 1-3 glucuronidic and ⁇ 1-4 glucosaminindic bonds.
  • Hyaluronic acid has a molecular weight within a range of 50,000 to 8,000,000 depending on the source, methods of preparation and determination. It is well known that hyaluronic acid and its salts, can be obtained from animal tissue and some bacteria, e.g. umbilical cords, vitrious humour, synovial fluid, rooster combs, pathological joints, groups A and C hymolitic streptococci and in skin, as well as from synthetic sources.
  • Phosphatidylcholine commonly known as lecithin
  • lecithin is a phosphatide found in all living organisms (plants and animals). It is a constituent of biological membranes and is involved in permeability, oxidative phosphorylation, phagocytosis, and chemical and electrical excitation. Lecithin has been identified in many animal tissues and organs such as in the brain, nervous system, liver, heart, lungs, kidneys, blood, milk, sperm, in micro-organisms and throughout the vegetable kingdom.
  • Lecithin is a mixture of the diglycerides of stearic, paermitic and oleic acids linked to the choline ester of phosphoric acid and can be represented by the general formula I
  • a solution or suspension comprising a surface active phospholipid, which optionally also contains hyaluronic acid (HA) or its salt, in an opthalmically suitable carrier of diluent, can treat and lubricate dry eyes and other conditions, as well as treating sore eyes.
  • HA hyaluronic acid
  • Other opthalmic applications include a lubricant for intra-ocular lenses and for post-cataract surgery, as well as in the new eye cosmetics.
  • a further use is in the treatment of conjunctivitis and similar conditions.
  • the addition of phospholipid to medicinal formulation for treating conjunctivitis assists in reducing the intense pain, especially when moving the eyelid relative to the eye, by providing lubrication and release action.
  • One aspect of the present invention concerns an artificial tear solution consisting of a suspension or solution of a phospholipid in an opthalmically suitable carrier or diluent.
  • Also disclosed is a method of treating/lubricating dry eyes which comprises applying to an eye an artificial tear solution consisting of a suspension or solution of a phospholipid in an opthalmically suitable carrier or diluent.
  • composition or treatment also includes hyaluronic acid, or a physiologically suitable salt thereof.
  • Another aspect of the invention is when the solution is used as a lubricant between the eyelid and the ocular surface or a contact lens.
  • Some phospholipid suspensions are viscous particularly those containing hyaluronic acid or its salts, but in the case of artificial tear formulations in accordance with the invention, the viscosity of the resultant formulation can be controlled, if necessary, by the concentration of the phospholipid solution, and if hyaluronic acid is present, by selection of hyaluronic acid of the appropriate molecular weight.
  • the artificial tear solution is diluted to a suitable viscosity, with an opthalmically suitable carrier or diluent for application to the eye.
  • CDP diglyceride choline phosphoglycerides
  • CDP diglyceride choline phosphoglycerides
  • Phosphodiol lipids acyl dihydroxyacetone phosphate alkyl dihydroxyacetone phosphate Phosphosphin ⁇ olipids spingomyelin (ceramide phosphorylcholine) ceramide phosphorylethanolamine ceramide phosphorylglycerophosphate ceramide phosphorylinositol-containing lipids
  • the phosphatidylcholine is suspended in solution by ultrasonic dispersion, if this is required.
  • the opthalmically suitable carrier or diluents useful in the present invention are substantially isotonic.
  • Substantially isotonic solutions are defined for present purposes as containing 270-310 milliosmoles/kg of solutes.
  • the tonicity adjusting agent is employed to bring the final solution tonicity within the stated ranges if not already there due to contributions of the other ingredients.
  • the preferred isotonicity adjusting agents are ionic salts, e.g. NaCl.
  • a solvent such as propylene glycol can be used to dissolve the phospholipid and other ingredients.
  • a solvent such as propylene glycol
  • chemically similar compounds to propylene glycol may be used, but such compounds should be suitable for opthalmic use.
  • a combination of propylene glycol or similar diluent together with water or saline solution may also be used.
  • the phospholipid may be present in an amount of about 20-200 mg/ml.
  • the amounts of the other ingredients can be adjusted accordingly, in accordance with opthalmic formulations known to be suitable for eye application.
  • Optional ingredients such as preservatives, buffers, surfactants, lubricants pharmaceutically active compounds and vasoconstricting (i.e. decongesting) agents may also be included in the solutions of this invention.
  • Preservatives useful in the present invention should not cause irritation to the eye. Strong binding of the preservative to contact lens is also undesirable since it causes the preservative to accumulate in the eye.
  • Preservatives preferred for use in the present solutions are any effective, non-irritating preservative which is compatible with hydrogels.
  • Some suitable preservatives include sorbic aid and EDTA.
  • the surfactants useful in the present invention are non-irritating to the eye and are, preferably, non-ionic.
  • the pharmaceutically active compounds useful in the solutions of this invention are those which have a prophylactic or therapeutic effect on eye disorders.
  • Some examples of pharmaceutically active compounds include, for example, compounds for the treatment of glaucoma, conjunctivitis, compounds for the treatment of red eyes and compounds for inflammatory ocular conditions.
  • the artificial tear solution of the present invention can impart excellent lubrication at low load which can, by conventional theory, be attributed to the fluid film of hyaluronic acid solution.
  • a boundary lubrication provided by an oligolamellar layer of phospholipid.
  • This solid lubrication is envisaged as being imparted in much the same way that colloidal graphite functions .when added to gear oil, that is providing a layer directly attached to the sliding surface and its counterface. It has been known for some time that a layer of phospholipid is directly attached to the ocular surface but no significance has hitherto been attribued to that finding.
  • the product can reduce the coefficient of friction to value between 0.02 to 0.006, and occasionally as low as 0.0007.
  • the major advantage of this product is at such very low friction was achieved at low velocities under high load (18 Kg/sq.cms).
  • the present artificial tear solution also has release properties, Lecithins are widely used as release agents, that is for the adhesive or antistick properties. This should also apply to the ocular surface, preventing sticking of a contact lens or the eyelid. Tests have shown that the force of adhesion by protein may be reduced by as much as 99%, in some situations.
  • the artificial tear solution of the present invention enhances the retention of fluid by the tear film in at least two ways. Firstly, it is well known that hyaluronic acid tends to retain water in loose association with its long hydrophilic molecules. Secondly, phospholipids might provide a onolayer reducing evaporation at the air-aqueous interface in much the same way that the industrial surfactants have been on dams to cut water evaporation.
  • the artificial tear solution of the present invention also reduces film rupture.
  • a water layer place on top of a hydrophobic surface has a high disjoining pressure tending to rupture the layer exposed to dry surface. This phenomenon is witnessed in siphoning water out of a Teflon-lined frying pan.
  • the layer ruptures spontaneously to expose dry surface is also hydrophobic and, therefore it will tend to rupture the tear film unless we blink every twenty seconds or so.
  • Our tests have demonstrated a contact angle of about 70 * on the ocular surface of bull's eyes by comparison with values of 108 * for teflon and 0° for wettable surfaces. The contact angle is the angle between the solid surface and the tangent to the air aqueous interface at the triple point where all three phases meet.
  • the disjoining pressure, and hence, the tendency for the film to rupture can be reduced if the surface energies of both the tissue-liquid and air-liquid interfaces are reduced.
  • the latter can be reduced by hyaluronic acid acting as a wetting acid, while the former can be reduced by locating a surfactant monolayer on the surface of the tear film to reduce surface tension. This could be achieved by the same monolayer reducing surface evaporation.
  • a phospholipid formulation was prepared by suspending 3mg/ml of DPL (phophatidyl choline) with lOmg/ml of hyaluronic acid by means of ultrasonic dispersion.
  • DPL phophatidyl choline
  • Example II Another test was mode of the lubricating ability, namely wear, of the same phospholipid formulation used in Example I.
  • a 4-ball test was performed by clamping together three ball bearings so that they cannot move and then applying a fourth so as to make three points of contact with the others.
  • a shaft welded to the fourth ball bearing is rotated at l,500rpm under a load of 40kg for one hour and the depths ofd the resulting grooves in the three fixed ball bearings measured by a mocroscope, and averaged. The groove averaged 0.70mm, with the use of the phospholipid formulation of Example I.
  • a formulation of a lecithin dissolved in propylene glycol was prepared, and found to have similar advantageous results to those of Example I.
  • a composition of lecithin and hyaluronic acid dissolved in propylene glycol also produced successful results.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Gyroscopes (AREA)
  • Prostheses (AREA)
  • Separation Using Semi-Permeable Membranes (AREA)
  • Materials For Medical Uses (AREA)

Abstract

An artificial tear composition for use in treating or preventing dry eye syndrome, or sore eyes, containing a phospholipid, and optionally hyaluronic acid or its salts, in a suitable carrier. The carrier is preferably an isotonic salt solution such as saline, or else propylene glycol. A method of treating sore eyes or dry eye syndrome using the composition as described. The method can be used to treat eyes wearing contact lenses.

Description

ARTIFICIAL TEARS
TECHNICAL FIELD
The present invention relates to an artificial tear composition and in particular to artificial tear compositions which contain phospholipids, and optionally hyaluronic acid or a salt thereof.
BACKGROUND ART
Artificial tears are currently available as eye drops and offer limited relief to dry eye syndrome. Such prior art formulations sometimes include hyaluronic acid, as this is a major component of natural tears.
It is an object of the present invention to provide an improved artificial tear solution which will substantially overcome, or ameliorate the abovementioned disadvantage of offering little relief to eyes to combat dry eye syndrome and also as treatment of sore eyes and other dry eye conditions.
Therefore, there is a need for an artificial tear composition which ideally would have one or more of the following properties: excellent lubrication to allow effortless sliding of the eyelid over the ocular surface or a contact lens; the capability to provide excellent of lubrication under high load bearing conditions relevant to an ill fitting contact lens and the pressure of high spot as the eye turns; reduction of fluid evaporation to maintain the tear film; reduction of the disjoining pressure tending to rupture the tear films and expose dry spots in the ocular surface; provision of a non-stick surface preventing adhesion of the ocular surface to a contact lens or eyelid; or provision of a biological barrier to invasion of the eye by impinging air-borne pathogens such as bacteria or viruses.
It is known from PCT/AU88/00322 that a lubricant composition comprising at least one surface active phospholipid, hyaluronic acid or a water soluble salt thereof in saline solution, is effective in the treatment of arthritis, osteoarthritis and rheumatic diseases by improving lubrication of surfaces in particular surfaces in the joints of animals and humans, and acting as a lubricant between tissue surfaces in contact with each other. As disclosed in PCT/AU88/000322, certain phospholipids, especially the disaturated phosphotidylcholines (lecithins), can give coefficients of kinetic friction of less than 0.01 and as low as 0.002. It was also found that these lower coefficients of friction could be
_2 obtained for loads as high as 13 Kgcm
Hyaluronic acid is a naturally occurring, high viscosity mucopolysaccharide having alternating β 1-3 glucuronidic and β 1-4 glucosaminindic bonds. Hyaluronic acid has a molecular weight within a range of 50,000 to 8,000,000 depending on the source, methods of preparation and determination. It is well known that hyaluronic acid and its salts, can be obtained from animal tissue and some bacteria, e.g. umbilical cords, vitrious humour, synovial fluid, rooster combs, pathological joints, groups A and C hymolitic streptococci and in skin, as well as from synthetic sources.
Phosphatidylcholine, commonly known as lecithin, is a phosphatide found in all living organisms (plants and animals). It is a constituent of biological membranes and is involved in permeability, oxidative phosphorylation, phagocytosis, and chemical and electrical excitation. Lecithin has been identified in many animal tissues and organs such as in the brain, nervous system, liver, heart, lungs, kidneys, blood, milk, sperm, in micro-organisms and throughout the vegetable kingdom.
Lecithin is a mixture of the diglycerides of stearic, paermitic and oleic acids linked to the choline ester of phosphoric acid and can be represented by the general formula I
CH^OCOR1
CH-OCOR2 (I)
CH2-OP— OCH2CH2N(CH_)3 ^O where R1 and R2 and fatty acid residues. Usually one acid is saturated and the other unsaturated.
It has now surprisingly been found that a solution or suspension comprising a surface active phospholipid, which optionally also contains hyaluronic acid (HA) or its salt, in an opthalmically suitable carrier of diluent, can treat and lubricate dry eyes and other conditions, as well as treating sore eyes. Other opthalmic applications include a lubricant for intra-ocular lenses and for post-cataract surgery, as well as in the new eye cosmetics.
A further use is in the treatment of conjunctivitis and similar conditions. The addition of phospholipid to medicinal formulation for treating conjunctivitis assists in reducing the intense pain, especially when moving the eyelid relative to the eye, by providing lubrication and release action.
DISCLOSURE OF INVENTION
One aspect of the present invention concerns an artificial tear solution consisting of a suspension or solution of a phospholipid in an opthalmically suitable carrier or diluent.
Also disclosed is a method of treating/lubricating dry eyes, which comprises applying to an eye an artificial tear solution consisting of a suspension or solution of a phospholipid in an opthalmically suitable carrier or diluent.
Preferably the composition or treatment also includes hyaluronic acid, or a physiologically suitable salt thereof.
Another aspect of the invention is when the solution is used as a lubricant between the eyelid and the ocular surface or a contact lens.
Some phospholipid suspensions are viscous particularly those containing hyaluronic acid or its salts, but in the case of artificial tear formulations in accordance with the invention, the viscosity of the resultant formulation can be controlled, if necessary, by the concentration of the phospholipid solution, and if hyaluronic acid is present, by selection of hyaluronic acid of the appropriate molecular weight. The artificial tear solution is diluted to a suitable viscosity, with an opthalmically suitable carrier or diluent for application to the eye.
Some of the phospholipids useful in the present invention are listed in the following table.
TABLE 1
Phosphoglycerides
phosphatidic acids cytidylic phosphoglycerides (CDP diglyceride) choline phosphoglycerides (CDP diglyceride) choline phosphoglycerides ethanolamine phosphoglycerides
N-methylethanolamine phosphoglycerides
N,N-dimethylethanolamine phosphoglycerides
N-acylethanolamine phosphoglyceride serine phosphoglycerides
N-2-(hydroxyethyl)alanine phosphoglyceride glycerol phosphoglycerides glycerophosphate phosphoglyceridesphosphatidylglycerol phosphoglyceride (diphosphatidylglycerol) mono and diacylglycerol phosphoglycerides (lysobisphosphatidic acids) glucosa inylglycerol phosphoglyceride 0-amino acid esters of glycerol phosphoglycerides inositol phosphoglyceride inositol monophosphate phosphoglyceride inositol diphosphate phosphoglyceride monomannosyl-hexa annosyl inositol phosphoglycerides glucose phosphoglyceride O-diglucosylglycerol phosphoglyceride
Phosphoglycolipids
diacyl (glycerylphosphoryldiglucosyl) glycerol
Phosphodiol lipids acyl dihydroxyacetone phosphate alkyl dihydroxyacetone phosphate Phosphosphinσolipids spingomyelin (ceramide phosphorylcholine) ceramide phosphorylethanolamine ceramide phosphorylglycerophosphate ceramide phosphorylinositol-containing lipids
Preferably the phosphatidylcholine is suspended in solution by ultrasonic dispersion, if this is required.
The opthalmically suitable carrier or diluents useful in the present invention are substantially isotonic. Substantially isotonic solutions are defined for present purposes as containing 270-310 milliosmoles/kg of solutes. The tonicity adjusting agent is employed to bring the final solution tonicity within the stated ranges if not already there due to contributions of the other ingredients.
The preferred isotonicity adjusting agents are ionic salts, e.g. NaCl.
Otherwise a solvent such as propylene glycol can be used to dissolve the phospholipid and other ingredients. Alternatively, chemically similar compounds to propylene glycol may be used, but such compounds should be suitable for opthalmic use.
A combination of propylene glycol or similar diluent together with water or saline solution may also be used.
If propylene glycol alone is used as the carrier, then the phospholipid may be present in an amount of about 20-200 mg/ml. The amounts of the other ingredients can be adjusted accordingly, in accordance with opthalmic formulations known to be suitable for eye application.
Optional ingredients such as preservatives, buffers, surfactants, lubricants pharmaceutically active compounds and vasoconstricting (i.e. decongesting) agents may also be included in the solutions of this invention.
Preservatives useful in the present invention should not cause irritation to the eye. Strong binding of the preservative to contact lens is also undesirable since it causes the preservative to accumulate in the eye.
Preservatives preferred for use in the present solutions are any effective, non-irritating preservative which is compatible with hydrogels. Some suitable preservatives include sorbic aid and EDTA.
Any biostatic amount of preservative which prevents contamination of the solutions may be used.
The surfactants useful in the present invention are non-irritating to the eye and are, preferably, non-ionic. The pharmaceutically active compounds useful in the solutions of this invention are those which have a prophylactic or therapeutic effect on eye disorders. Some examples of pharmaceutically active compounds include, for example, compounds for the treatment of glaucoma, conjunctivitis, compounds for the treatment of red eyes and compounds for inflammatory ocular conditions.
The artificial tear solution of the present invention can impart excellent lubrication at low load which can, by conventional theory, be attributed to the fluid film of hyaluronic acid solution. At points of high load where fluid will be squeezed out from between the surfaces sliding at such low velocities, there is excellent boundary lubrication provided by an oligolamellar layer of phospholipid. This solid lubrication is envisaged as being imparted in much the same way that colloidal graphite functions .when added to gear oil, that is providing a layer directly attached to the sliding surface and its counterface. It has been known for some time that a layer of phospholipid is directly attached to the ocular surface but no significance has hitherto been attribued to that finding.
To summarise its lubricating properties, the product can reduce the coefficient of friction to value between 0.02 to 0.006, and occasionally as low as 0.0007. The major advantage of this product is at such very low friction was achieved at low velocities under high load (18 Kg/sq.cms).
The present artificial tear solution also has release properties, Lecithins are widely used as release agents, that is for the adhesive or antistick properties. This should also apply to the ocular surface, preventing sticking of a contact lens or the eyelid. Tests have shown that the force of adhesion by protein may be reduced by as much as 99%, in some situations.
The artificial tear solution of the present invention enhances the retention of fluid by the tear film in at least two ways. Firstly, it is well known that hyaluronic acid tends to retain water in loose association with its long hydrophilic molecules. Secondly, phospholipids might provide a onolayer reducing evaporation at the air-aqueous interface in much the same way that the industrial surfactants have been on dams to cut water evaporation.
The artificial tear solution of the present invention also reduces film rupture. A water layer place on top of a hydrophobic surface has a high disjoining pressure tending to rupture the layer exposed to dry surface. This phenomenon is witnessed in siphoning water out of a Teflon-lined frying pan. When the depth of the water is reduced to about 1 to 1.5 millimetres, the layer ruptures spontaneously to expose dry surface is also hydrophobic and, therefore it will tend to rupture the tear film unless we blink every twenty seconds or so. Our tests have demonstrated a contact angle of about 70* on the ocular surface of bull's eyes by comparison with values of 108* for teflon and 0° for wettable surfaces. The contact angle is the angle between the solid surface and the tangent to the air aqueous interface at the triple point where all three phases meet.
The disjoining pressure, and hence, the tendency for the film to rupture can be reduced if the surface energies of both the tissue-liquid and air-liquid interfaces are reduced. The latter can be reduced by hyaluronic acid acting as a wetting acid, while the former can be reduced by locating a surfactant monolayer on the surface of the tear film to reduce surface tension. This could be achieved by the same monolayer reducing surface evaporation.
MODES FOR CARRYING OUT THE INVENTION
The invention is now described with reference to examples.
EXAMPLE 1
A determination was made of the lubricating effect of a phospholipid formulation on an eye. A phospholipid formulation was prepared by suspending 3mg/ml of DPL (phophatidyl choline) with lOmg/ml of hyaluronic acid by means of ultrasonic dispersion.
10 eyes from five freshly killed sheep were tested on a friction machine, and gave coefficients of kinetic friction (^CL) ranging from 0.01 to 0.04. The same eyes were then rinsed for 10 minutes in a solvent (2:1 chloroform: methanol) to remove the natural phospholipid present, and tested again. The friction was much increased and, in fact, was off the scale of the transducer, which corresponds to.✓*<■>0.1. When the phospholipid lubricant formulation was then applied to the eyes and the coefficients of kinetic friction determined again, __✓£< was in the range of 0.01 to 0.04.
EXAMPLE II
Another test was mode of the lubricating ability, namely wear, of the same phospholipid formulation used in Example I. A 4-ball test was performed by clamping together three ball bearings so that they cannot move and then applying a fourth so as to make three points of contact with the others. A shaft welded to the fourth ball bearing is rotated at l,500rpm under a load of 40kg for one hour and the depths ofd the resulting grooves in the three fixed ball bearings measured by a mocroscope, and averaged. The groove averaged 0.70mm, with the use of the phospholipid formulation of Example I. When the test was repeated with another phospholipid formulation, but this time increasing the phospholipid concentration to 4mg/ml, with the hyaluronic acid remaining at lOmg/ml, the value for the average depth of the resulting grooves was 0.69mm.
These results demonstrate the effectiveness of phospholipids as lubricants. The test results using phospholipids compare favourably with such values as 1.4mm for milk, 0.35mm for the very best lubricating oils, and 0.7 to 0.9mm for typical commercial aqueous lubricants.
EXAMPLE III
A formulation of a lecithin dissolved in propylene glycol was prepared, and found to have similar advantageous results to those of Example I. A composition of lecithin and hyaluronic acid dissolved in propylene glycol also produced successful results.

Claims

THE CLAIMS
1. An artificial tear composition, for the prophylaxis or treatment of dry eye syndrome and other conditions that cause sore or dry eyes, which comprises a suspension or solution of a phospholipid, and optionally hyaluronic acid or a physiologically suitable salt thereof, in an ophthalmically suitable carrier.
2. The artificial tear composition of claim 1 wherein the carrier is saline solution.
3. The artificial tear composition of claim 1 wherein said carrier is propylene glycol.
4. The artifical tear composition of claim 1 which contains hyaluronic acid or a physiologically suitable salt thereof, selected so as to optimize the viscosity of the composition.
5. The artificial tear solution of claim 1 which also contains any one or more of preservatives, buffers, surfactants, lubricants, phamaceutically active compounds or vasoconstricting agents, suitable for opthalmic use.
6. A method for the prophylaxis or treatment of dry eye syndrome or other conditions that cause dry or sore eyes, which comprises applying to an eye an artificial tear composition of a phospholipid, and optionally hyaluronic acid or a physiologically acceptable salt thereof, in an opthalmically suitable carrier. 7. The method of claim 6 wherein the carrier is saline solution.
8. The method of claim 6 wherein the carrier is propylene glycol.
9. The method of claim 6 wherein the eye has a contact lens thereon.
EP19910904702 1990-02-22 1991-02-22 Artificial tears Withdrawn EP0516685A4 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
AU8763/90 1990-02-22
AUPJ876390 1990-02-22

Publications (2)

Publication Number Publication Date
EP0516685A1 EP0516685A1 (en) 1992-12-09
EP0516685A4 true EP0516685A4 (en) 1993-03-17

Family

ID=3774513

Family Applications (1)

Application Number Title Priority Date Filing Date
EP19910904702 Withdrawn EP0516685A4 (en) 1990-02-22 1991-02-22 Artificial tears

Country Status (4)

Country Link
EP (1) EP0516685A4 (en)
JP (1) JPH05503527A (en)
AU (1) AU655919B2 (en)
WO (1) WO1991012808A1 (en)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU1294195A (en) * 1993-11-24 1995-06-13 Ocutech, Inc. Compositions and methods for the treatment of dry eyes and other ocular disorders
AU699375B2 (en) * 1995-12-19 1998-12-03 Macnaught Medical Pty Limited Phospholipid and propylene glycol based lubricant
AUPN723395A0 (en) * 1995-12-19 1996-01-18 Macnaught Medical Pty Limited Lubrication methods
ES2127110B1 (en) * 1996-05-24 1999-12-01 Univ Valladolid PROCEDURE TO VARY THE ELECTRICAL PROPERTIES OF THE HUMAN EYE MOCO AND SUBSTITUTES FOR OPHTHALMIC USE.
IL120005A (en) * 1997-01-14 2000-08-31 Ramot University Authority Of Pharmaceutical compositions for the treatment of the eye
GB9716376D0 (en) * 1997-08-01 1997-10-08 Isis Innovation Artificial tear formulation
EP0982025A1 (en) * 1998-08-28 2000-03-01 Wilhelm Prof. Dr. Stoffel Synthetic tear fluid
DE60007548T2 (en) 1999-11-09 2004-06-17 Alcon, Inc. OMEGA CHAIN-MODIFIED HYDROXYEICOSATETRAIC ACID DERIVATIVES USED IN THE TREATMENT OF THE "DRY EYE" DISEASE
JP2003513950A (en) 1999-11-09 2003-04-15 アルコン，インコーポレイテッド Benzenoid derivatives of 15-hydroxyeicosatetraenoic acid and methods used to treat dry eye disorders
AU776258B2 (en) 1999-11-09 2004-09-02 Alcon Inc. Heteroatom-interrupted analogs of 15-hydroxyeicosatetraenoic acid and methods of use
US6353032B1 (en) 1999-11-09 2002-03-05 Alcon Universal Ltd. Phospholipids of hydroxyeicosatetraenoic acid-like derivatives and methods of use
WO2001034550A2 (en) 1999-11-09 2001-05-17 Alcon Universal Ltd. 15-hydroxyeicosatetraenoic acid analogs with enhanced metabolic stability and methods of their use in treating dry eye disorders
AU1101301A (en) 1999-11-09 2001-06-06 Alcon Universal Limited 2,2-difluoro 15-hydroxyeicosatetraenoic acid analogs and methods of use
US6803385B2 (en) 1999-11-09 2004-10-12 Alcon, Inc. Hydroxyeicosatetraenoic acid analogs and methods of their use in treating dry eye disorders
US6552084B2 (en) 1999-11-09 2003-04-22 Alcon Universal Ltd. Hydroxyeicosatetraenoic acid analogs and methods of their use in treating dry eye disorders
CA2386619A1 (en) 1999-11-09 2001-05-17 Alcon, Inc. Compositions containing hydroxyeicosatetraenoic acid derivatives and methods of use in treating dry eye disorders
US6458854B2 (en) 1999-11-09 2002-10-01 Alcon Universal Ltd. Phospholipids of hydroxyeicosatetraenoic acid-like derivatives and methods of use
EP1228028B1 (en) 1999-11-09 2005-08-10 Alcon Inc. Hydroxyeicosatetraenoate salts, compositions and methods of use in treating dry eye disorders
CA2386333A1 (en) 1999-11-09 2001-05-17 Alcon, Inc. 3-heteroatom substituted and two carbon homologs 15-hete and methods of use
TR200201252T2 (en) 1999-11-09 2003-02-21 Alcon, Inc. 15-Hydroxyiecosatetraenoic acid-related compounds and their methods of use
US6565861B1 (en) 2000-02-11 2003-05-20 Isis Innovation Limited Artificial tear formulation
CA2489528A1 (en) * 2002-06-20 2003-12-31 Novartis Consumer Health S.A. Nasal compositions comprising a mucopolysaccharide and propylene glycol
US20050196370A1 (en) * 2003-03-18 2005-09-08 Zhi-Jian Yu Stable ophthalmic oil-in-water emulsions with sodium hyaluronate for alleviating dry eye
FR2876581B1 (en) 2004-10-20 2007-05-18 Interpharm Dev BIOADHESIVE COMPOSITION WITH PROGRAMMED RELEASE
KR20090053892A (en) 2006-07-25 2009-05-28 오스모티카 코프. eye drops
IT1394223B1 (en) 2009-05-15 2012-06-01 Thea Sas Lab KIT FOR ASSESSMENT AND CUSTOMIZED SELECTION OF ARTIFICIAL TEARS
WO2011138228A1 (en) * 2010-05-04 2011-11-10 Trb Chemedica Ag Aqueous composition for ophthalmic or dermal use
DE102010023949A1 (en) * 2010-06-16 2011-12-22 F. Holzer Gmbh In-situ lecithin microemulsion gel formulation
AU2016396661B2 (en) * 2016-03-08 2023-01-19 University Of Utah Research Foundation Cross-linking agents and associated methods
KR102488796B1 (en) * 2016-07-18 2023-01-13 리젠트리 엘엘씨 How to treat dry eye syndrome

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0037043A1 (en) * 1980-03-21 1981-10-07 The Wellcome Foundation Limited Stabilised ophthalmic formulation
GB2196255A (en) * 1986-10-14 1988-04-27 Res & Dev Co Ltd Eyedrops
WO1988003018A1 (en) * 1986-10-21 1988-05-05 Liposome Technology, Inc. Liposome composition for treating dry eye
WO1989001777A1 (en) * 1987-08-25 1989-03-09 Macnaught Pty. Limited Lubricant composition for rheumatism
WO1991001765A1 (en) * 1989-07-27 1991-02-21 Cozzarelli, Frank, Jr. A phospholipid delivery system

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4421748A (en) * 1982-07-13 1983-12-20 Trager Seymour F Artificial tear aid
DE3316012A1 (en) * 1983-05-03 1984-11-08 Rainer Richard Otto Dr.med. 3104 Unterlüß Reifenrath Pharmaceutical product for the treatment and prophylaxis of infections and of coughs and obstructive airway disorders and process for the preparation thereof
US4804539A (en) * 1986-07-28 1989-02-14 Liposome Technology, Inc. Ophthalmic liposomes
US4839175A (en) * 1986-07-28 1989-06-13 Liposome Technology, Inc. Liposomes with enhanced retention on mucosal tissue
US4914088A (en) * 1987-04-02 1990-04-03 Thomas Glonek Dry eye treatment solution and method
IL93996A0 (en) * 1989-04-04 1991-01-31 Alcon Lab Inc Pharmaceutical composition containing a liposome

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0037043A1 (en) * 1980-03-21 1981-10-07 The Wellcome Foundation Limited Stabilised ophthalmic formulation
GB2196255A (en) * 1986-10-14 1988-04-27 Res & Dev Co Ltd Eyedrops
WO1988003018A1 (en) * 1986-10-21 1988-05-05 Liposome Technology, Inc. Liposome composition for treating dry eye
WO1989001777A1 (en) * 1987-08-25 1989-03-09 Macnaught Pty. Limited Lubricant composition for rheumatism
WO1991001765A1 (en) * 1989-07-27 1991-02-21 Cozzarelli, Frank, Jr. A phospholipid delivery system

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See also references of WO9112808A1 *

Also Published As

Publication number Publication date
JPH05503527A (en) 1993-06-10
AU7307691A (en) 1991-09-18
WO1991012808A1 (en) 1991-09-05
AU655919B2 (en) 1995-01-19
EP0516685A1 (en) 1992-12-09

Similar Documents

Publication Publication Date Title
AU655919B2 (en) Artificial tears
US4421748A (en) Artificial tear aid
US5578586A (en) Dry eye treatment process and solution
JPH03501250A (en) Lubricating composition for rheumatism
RU2197970C2 (en) Compositions and methods used for decreasing ocular hypertension
RU2495661C2 (en) Pharmaceutical formulations of non-polar and polar lipids for ophthalmological application
US4866049A (en) Ophthalmic compositionn and method of using same
RU2394552C2 (en) Bioresolvable fillers formed by phospholipid liposomes and hyaluronic acid and/or its derivatives
JP2008526886A (en) Dry eye treatment
WO2001085179A3 (en) Biological joint lubricant composition and method of applying
US20230080018A1 (en) Phosphatidylcholine lipid liposomes as boundary lubricants in aqueous media
WO2009084069A2 (en) Ocular solution with organic lycopene
CA2949203C (en) Composition for treating the eye
ZA200601179B (en) Cosmetic composition promoting oxygen transport into the skin
JP2007211007A (en) O / W emulsion aqueous eye drops
CA1283864C (en) Body lubricating and cleansing fluid
WO1991012026A1 (en) Means of reducing surgical adhesions
KR20170001161A (en) Elastic liposome composition and cosmetic composition comprising the same
WO2011138228A1 (en) Aqueous composition for ophthalmic or dermal use
WO2007076274A2 (en) Artificial tear solution containing poly (ethylene glycol) peg lipids
Angayarkanni et al. Lipid-bilayer assemblies on polymer-bearing surfaces: The nature of the slip plane in asymmetric boundary lubrication
US20190038555A1 (en) Bicontinuous microemulsions and methods of use thereof
JPWO2006009101A1 (en) Contact lens mounting solution
AU620821B2 (en) Hyaluronic acid lubricating compounds
Torrent-Burgués et al. Lipid artificial tears at a mimetic ocular interface

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 19920909

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FR GB GR IT LI LU NL SE

A4 Supplementary search report drawn up and despatched

Effective date: 19930125

AK Designated contracting states

Kind code of ref document: A4

Designated state(s): AT BE CH DE DK ES FR GB GR IT LI LU NL SE

RIN1 Information on inventor provided before grant (corrected)

Inventor name: HILLS, BRIAN, ANDREW

17Q First examination report despatched

Effective date: 19950523

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 19951205